A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing the products through our field sales organization. We are a controlled subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”). 2024 Highlights and Events On November 1, 2024, the FDA approved EmrosiTM (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29 (“Emrosi”), for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed by Journey in collaboration with Dr.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 58M | 55M | 60M | 71M | 63M | 45M |
| Net Income | -8.7M | -15M | -3.9M | -30M | -44M | 5.3M |
| EPS | $-0.35 | $-0.72 | $-0.21 | $-1.69 | $-4.32 | $0.49 |
| Free Cash Flow | 0 | -24M | 240K | -34M | -2.2M | -2.7M |
| ROIC | -16.6% | -32.6% | -11.0% | -80.5% | -65.5% | 79.8% |
| Gross Margin | - | 62.1% | 61.6% | 56.7% | 49.2% | 67.2% |
| Debt/Equity | 0.97 | 1.24 | 0.72 | 1.17 | 1.31 | 0.51 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -5.5M | -14M | -2.1M | -28M | -35M | 7.9M |
| Operating Margin | -9.5% | -24.8% | -3.5% | -38.8% | -55.2% | 17.6% |
| ROE | -33.5% | -72.6% | -18.9% | -174.5% | -104.6% | 51.3% |
| Shares Outstanding | 6M | 20M | 18M | 18M | 10M | 11M |
| Metric | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 45M | 63M | 71M | 60M | 55M | 58M |
| Gross Margin | 67.2% | 49.2% | 56.7% | 61.6% | 62.1% | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | 7.9M | -35M | -28M | -2.1M | -14M | -5.5M |
| Op. Margin | 17.6% | -55.2% | -38.8% | -3.5% | -24.8% | -9.5% |
| Net Income | 5.3M | -44M | -30M | -3.9M | -15M | -8.7M |
| Net Margin | 11.9% | -69.7% | -41.7% | -6.5% | -26.6% | -15.0% |
| Non-Recurring | 0 | 0 | 0 | 3.1M | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 79.8% | -65.5% | -80.5% | -11.0% | -32.6% | -16.6% |
| ROE | 51.3% | -104.6% | -174.5% | -18.9% | -72.6% | -33.5% |
| ROA | 10.2% | -45.2% | -28.2% | -5.0% | -18.7% | -10.2% |
| Cash Flow | ||||||
| Op. Cash Flow | 5.1M | -2.2M | -14M | 5.2M | -9.1M | -3.9M |
| Free Cash Flow | -2.7M | -2.2M | -34M | 240K | -24M | 0 |
| Owner Earnings | 5.0M | -7.1M | -22M | -1.1M | -19M | -13M |
| CapEx | 7.9M | 0 | 20M | 5.0M | 15M | 0 |
| Maint. CapEx | 5K | 2.5M | 4.3M | 3.8M | 3.4M | 3.4M |
| Growth CapEx | 7.9M | N/A | 16M | 1.2M | 12M | 0 |
| D&A | 5K | 2.5M | 4.3M | 3.8M | 3.4M | 3.4M |
| CapEx/OCF | N/A | N/A | N/A | 95.4% | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 153K | 2.5M | 4.4M | 2.6M | 6.1M | 6.1M |
| Debt Repayment | 0 | 2.0M | 214K | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -3.0M | N/A | -12M | -13M | 4.6M | 211K |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | 25M |
| Long-Term Debt | 5.2M | N/A | 20M | 15M | 25M | 25M |
| Debt/Equity | 0.51 | 1.31 | 1.17 | 0.72 | 1.24 | 0.97 |
| Interest Coverage | 11.2 | -5.0 | -13.6 | -1.2 | -5.1 | -5.1 |
| Equity | 10M | 42M | 17M | 20M | 20M | 26M |
| Total Assets | 52M | 97M | 105M | 77M | 80M | 85M |
| Total Liabilities | 42M | 55M | 88M | 56M | 60M | 59M |
| Intangibles | 30M | 25M | 54M | 41M | 64M | 64M |
| Retained Earnings | 5.1M | -39M | -69M | -72M | -87M | -87M |
| Working Capital | 7.2M | 33M | 11M | 15M | 13M | 13M |
| Current Assets | 35M | 84M | 78M | 56M | 48M | 48M |
| Current Liabilities | 28M | 52M | 67M | 42M | 35M | 35M |
| Per Share Data | ||||||
| EPS | 0.49 | -4.32 | -1.69 | -0.21 | -0.72 | -0.35 |
| Owner EPS | 0.46 | -0.70 | -1.27 | -0.06 | -0.92 | -2.24 |
| Book Value | 0.95 | 4.13 | 0.97 | 1.11 | 0.98 | 4.32 |
| Cash Flow/Share | 0.48 | -0.21 | -0.77 | 0.29 | -0.45 | -0.87 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 10.8M | 10.2M | 17.5M | 18.3M | 20.4M | 6.0M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -15.0 |
| P/FCF | N/A | N/A | N/A | 486.2 | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 1.3 | 1.2 | 5.7 | 4.2 | 1.2 |
| Price/Sales | N/A | 1.2 | 0.9 | 0.8 | 1.8 | 0.5 |
| FCF Yield | N/A | -4.0% | -162.1% | 0.2% | -28.4% | N/A |
| Market Cap | N/A | 55M | 21M | 117M | 85M | 32M |
| Avg. Price | N/A | 7.44 | 3.62 | 2.52 | 4.79 | 5.26 |
| Year-End Price | N/A | 5.40 | 1.18 | 6.36 | 4.17 | 5.26 |
Journey Medical Corp passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 59.4%.
Journey Medical Corp (DERM) has a 5-year average return on invested capital (ROIC) of -22.0%. This is below average and may indicate limited pricing power.
Journey Medical Corp (DERM) has a market capitalization of $32M. It is classified as a small-cap stock.
Journey Medical Corp (DERM) does not currently pay a regular dividend.
Journey Medical Corp (DERM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Journey Medical Corp (DERM) reported annual revenue of $55 million in its most recent fiscal year, based on SEC EDGAR filings.
Journey Medical Corp (DERM) has a net profit margin of -26.6%. The company is currently unprofitable.
Journey Medical Corp (DERM) generated $-24 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Journey Medical Corp (DERM) has a debt-to-equity ratio of 1.24. This indicates moderate leverage.
Journey Medical Corp (DERM) reported earnings per share (EPS) of $-0.72 in its most recent fiscal year.
Journey Medical Corp (DERM) has a return on equity (ROE) of -72.6%. A negative ROE may indicate losses or negative equity.
Journey Medical Corp (DERM) has a 5-year average gross margin of 59.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for Journey Medical Corp (DERM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Journey Medical Corp (DERM) has a book value per share of $0.98, based on its most recent annual SEC filing.
No recent press releases.